Outflow from losses and R&D

We recorded net losses in 2021, 2022 and 2023, and recorded adjusted net loss (non-IFRS measure) and net operating cash outflow during the Track Record Period.

Summary · p. 27

During the Track Record Period, we had funded our cash requirements primarily with capital contribution from shareholders and financing through the Pre-IPO Investments.

Summary · p. 27

In 2022 and the six months ended June 30, 2023, we recorded net operating cash outflow of RMB93.6 million and RMB130.8 million, respectively.

Summary · p. 1

We incurred net losses during the Track Record Period and net operating cash outflow in 2022 and the six months ended June 30, 2023, as we have been focusing on constructing and establishing our medical institutions and growing our business, and large initial investments is mandatory for hospital industry due to its heavy-asset nature.

Summary · p. 14

We successfully increased our net operating cash inflow from RMB50.6 million in 2020 to RMB151.2 million in 2021.

Summary · p. 14

Our net operating cash outflow in 2020, 2021 and 2022 and the six months ended June 30, 2023 was RMB75.2 million, RMB180.5 million, RMB523.1 million and RMB273.8 million, respectively.

Financial Information · p. 309

Meanwhile, we expect to record a substantial amount of net loss and net operating cash outflow in 2023, as we continue to invest in expanding our production volume, R&D activities as well as sales and marketing activities.

Summary · p. 15

During the Track Record Period, we had funded our cash requirements primarily with capital contribution from shareholders and financing through the Pre-IPO Investments.

Business · p. 228

For FY2020, FY2021, FY2022, 6M2022 and 6M2023, we had net cash used in operating activities of RMB602.6 million, RMB680.7 million, RMB543.5 million, RMB115.1 million and RMB526.5 million, respectively, including R&D expenses, selling and marketing expenses, general and administrative expenses to develop and promote our new products and services.

Business · p. 370

As such, we expect to continue to have net cash outflows from operating activities in the near future. We anticipate that we will only become profitable when we can obtain sufficient purchase orders and expand our sales to take advantage of economies of scale.

Business · p. 370

Despite our continuous growth in revenue and volume and our narrowing negative gross margin from 2020 to 2022, we incurred operating losses and net operating cash outflow, mainly due to (i) the gross loss incurred in our operations in China during the three years ended December 31, 2022 and (ii) to a much lesser extent, our cross-border and the New Markets businesses in 2022.

Business · p. 213

In addition, in view of our net cash outflow from operating activities during the Track Record Period, we plan to ensure our working capital sufficiency by leveraging the above-mentioned measures to narrow down our net loss and improve our profitability, which will also translate into improved net operating cash flows.

Summary · p. 22

We believe that potential external financing sources, including those to which we will gain access after the Global Offering, will provide additional funding to fuel our business operation and expansion until we achieve profitability and positive operating cash flow.

Summary · p. 22

We have recorded net cash used in operating activities of RMB452.9 million, RMB770.0 million, RMB779.6 million, RMB169.4 million and RMB461.2 million, in 2020, 2021, 2022 and in the three months ended March 31, 2022 and 2023, respectively, primarily due to the net loss recorded and increases in our trade receivables, mainly due to our business growth.

Summary · p. 19

To ensure working capital sufficiency, we plan to enhance our working capital management efficiency, improve our management of trade receivables and increase the focus on trade receivable collection.

Summary · p. 19

Our net cash used in operating activities was RMB190.5 million, RMB238.7 million, and RMB79.2 million in 2021, 2022, and the four months ended April 30, 2023, respectively, primarily due to the significant research and development expenses and administrative expenses we incurred during the Track Record Period without generating any revenue from sales of our drug candidates.

Financial Information · p. 393

During the Track Record Period and up to the Latest Practicable Date, we have primarily funded our working capital requirements through proceeds from private equity financings.

Financial Information · p. 393

We recorded net cash used in operating activities of RMB485.9 million and RMB270.8 million for the years ended December 31, 2021 and 2022, respectively.

Financial Information · p. 526

Our primary uses of cash during the Track Record Period were to fund our research and development activities, the construction of our research and development and manufacturing facilities, and purchase of equipment, machinery and intangible assets.

Financial Information · p. 526

As of April 30, 2023, the latest practicable date for determining our indebtedness, we had cash and cash equivalents of RMB1,342.2 million.

Financial Information · p. 527

Net cash flows used in operating activities | (159,877) | (236,190)

Financial Information · p. 421

Our primary uses of cash are to fund the R&D activities of our Core Product and other product candidates, administrative expenses and other recurring expenses.

Financial Information · p. 421

Our Directors are of the opinion that, taking into account the financial resources available, including cash and cash equivalents, time deposits over three months and the estimated net proceeds from the Listing, as well as our cash burn rate, we have sufficient working capital to cover at least 125% of our costs, including selling and distribution expense, R&D costs, administrative expenses for at least the next 12 months from the date of this Prospectus.

Financial Information · p. 424

During the Track Record Period, we primarily funded our working capital requirements through capital contributions from our shareholders and private equity financing.

Financial Information · p. 393

Our net cash used in operating activities was RMB19.2 million and RMB77.3 million in 2021 and 2022, respectively.

Financial Information · p. 393

As our business develops and expands, we expect to generate net cash from our operating activities through the sales revenue of our future commercialized products.

Financial Information · p. 393

We recorded net cash outflow from operating activities of RMB83.4 million, RMB65.5 million, RMB156.0 million and RMB186.1 million for the fiscal years ended March 31, 2019, 2020 and 2022 and the six months ended September 30, 2022 respectively, which were attributable primarily to our operating loss for the same periods.

Summary · p. 16

This was primarily due to our narrowed operating loss during the same year as a result of (i) our efforts to optimize our internal organizational structure and headcount, and to a lesser extent, (ii) the reduction in the amount of social insurance contributions for our operation and product support staff due to the PRC government’s relief policies in response to the COVID-19 pandemic.

Summary · p. 17

While these investments typically would not translate into immediate financial returns and have in part contributed to our historical operating loss positions, we believe that they are indispensable to achieving our current scale and market leadership, as well as long-term path to profitability.

Summary · p. 17